tiprankstipranks
Trending News
More News >
VYNE Therapeutics (VYNE)
NASDAQ:VYNE
US Market

VYNE Therapeutics (VYNE) AI Stock Analysis

Compare
1,829 Followers

Top Page

VY

VYNE Therapeutics

(NASDAQ:VYNE)

Rating:41Neutral
Price Target:
$1.00
▼( -3.85% Downside)
VYNE Therapeutics faces significant financial and operational challenges, evidenced by negative profitability and cash flow concerns. Technical indicators reinforce a bearish outlook, with the stock trading below major averages. The lack of valuation appeal, due to negative earnings and no dividend, further underscores the stock's current risks.
Positive Factors
Clinical Trials and Efficacy
Repibresib gel showed rapid and meaningful clinical benefit with a favorable safety profile in a Phase Ib study, indicating promising therapeutic potential.
Financial Stability
VYNE Therapeutics has $50.3 million in cash, which is expected to fund operations into the second half of 2026, ensuring financial stability.
Product Differentiation
Repibresib is administered once-daily and is not expected to have a black-box warning, offering advantages over the current standard of care.
Negative Factors
Regulatory Challenges
The FDA has placed a clinical hold on the Phase Ib study evaluating VYN202 due to testicular toxicity observed in dogs, posing a significant regulatory challenge.
Research and Development Setbacks
The company has suspended all screening, enrollment, and dosing in the VYN202 study and is working with the FDA to resolve the hold, indicating a setback in research and development efforts.

VYNE Therapeutics (VYNE) vs. SPDR S&P 500 ETF (SPY)

VYNE Therapeutics Business Overview & Revenue Model

Company DescriptionVYNE Therapeutics (VYNE) is a biopharmaceutical company focused on developing and commercializing innovative therapies in dermatology and other disease areas. The company is dedicated to advancing its proprietary pipeline of treatments targeting inflammatory and immunomodulatory conditions. VYNE's core products include topical treatments for dermatological conditions such as acne and rosacea, with a focus on delivering effective and patient-friendly solutions.
How the Company Makes MoneyVYNE Therapeutics generates revenue primarily through the sale of its dermatological products. The company markets and sells its proprietary topical treatments to healthcare providers, pharmacies, and directly to consumers. Additionally, VYNE may engage in strategic partnerships or licensing agreements with other pharmaceutical companies to co-develop or distribute its therapies, which can provide additional revenue streams. The company's earnings are driven by product sales, potential milestone payments, and royalties from licensing agreements.

VYNE Therapeutics Financial Statement Overview

Summary
VYNE Therapeutics faces significant financial challenges with persistent losses and cash flow issues. The balance sheet is relatively strong with low leverage, but ongoing unprofitability and negative cash flows raise concerns about financial sustainability. The company's financial position is undermined by the biotechnology industry's volatility.
Income Statement
40
Negative
VYNE Therapeutics has shown a significant decline in revenue over recent years, with a steep drop from 2020 to 2024. The gross profit margin is positive, but the company is facing substantial operating losses as evidenced by negative EBIT and EBITDA margins. The net profit margin is also significantly negative, highlighting persistent unprofitability. These metrics indicate challenges in achieving revenue growth and controlling costs.
Balance Sheet
55
Neutral
The company has maintained a healthy equity position with a low debt-to-equity ratio, suggesting limited leverage risk. However, there is a consistent decrease in stockholders' equity over the last few years. The equity ratio is relatively strong, indicating a stable asset base primarily funded by equity. Despite these strengths, profitability remains an issue.
Cash Flow
45
Neutral
Operating cash flow is consistently negative, reflecting ongoing cash burn, which is a concern for sustainability. Free cash flow has been negative, with limited growth in free cash flow, suggesting cash management challenges. The company has relied on financing activities to supplement cash needs, which could pose future risks if access to capital markets becomes constrained.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
501.00K424.00K477.00K14.76M20.99M
Gross Profit
501.00K424.00K477.00K11.41M19.60M
EBIT
-43.64M-29.26M-34.30M-68.03M-113.47M
EBITDA
-43.63M-29.26M-34.22M-38.94M-251.09M
Net Income Common Stockholders
-39.83M-28.45M-33.95M-73.33M-255.57M
Balance SheetCash, Cash Equivalents and Short-Term Investments
61.52M93.25M30.91M42.25M58.59M
Total Assets
66.91M97.69M40.76M67.05M93.74M
Total Debt
99.00K214.00K-349.00K349.00K34.78M
Net Debt
-19.83M-30.41M-31.26M-41.90M-22.78M
Total Liabilities
14.82M8.95M9.56M18.41M56.25M
Stockholders Equity
52.09M88.73M31.20M48.64M37.49M
Cash FlowFree Cash Flow
-34.09M-25.34M-29.20M-56.37M-137.19M
Operating Cash Flow
-33.97M-25.34M-29.20M-56.37M-137.08M
Investing Cash Flow
23.36M-57.35M15.67M1.03M89.11M
Financing Cash Flow
-141.00K82.39M1.65M39.78M61.81M

VYNE Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.04
Price Trends
50DMA
1.53
Negative
100DMA
2.10
Negative
200DMA
2.20
Negative
Market Momentum
MACD
-0.15
Positive
RSI
29.05
Positive
STOCH
8.39
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYNE, the sentiment is Negative. The current price of 1.04 is below the 20-day moving average (MA) of 1.27, below the 50-day MA of 1.53, and below the 200-day MA of 2.20, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 29.05 is Positive, neither overbought nor oversold. The STOCH value of 8.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VYNE.

VYNE Therapeutics Risk Analysis

VYNE Therapeutics disclosed 63 risk factors in its most recent earnings report. VYNE Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

VYNE Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
53
Neutral
$5.14B3.03-43.89%2.83%16.75%-0.06%
46
Neutral
$35.76M-1205.58%203.23%13.57%
41
Neutral
$16.66M-66.15%43.03%81.75%
41
Neutral
$25.67M597.53%88.13%92.45%
41
Neutral
$28.43M-853.05%34.97%
32
Underperform
$22.01M-1738.36%-43.55%-293.22%
30
Underperform
$36.46M-2880.11%31.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VYNE
VYNE Therapeutics
1.04
-1.54
-59.69%
PLUR
Pluri
4.56
-1.46
-24.25%
DARE
Daré Bioscience
2.90
-4.51
-60.86%
CLNN
Clene
2.37
-4.65
-66.24%
PYPD
PolyPid
2.78
-1.74
-38.50%
NRSN
Neurosense Therapeutics Ltd.
1.52
0.35
29.91%

VYNE Therapeutics Corporate Events

Shareholder MeetingsBusiness Operations and Strategy
VYNE Therapeutics Sees Strong Shareholder Support for Growth
Positive
Dec 12, 2024

VYNE Therapeutics’ stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing shares available for issuance and adjusting share recycling policies. During the annual meeting, all five proposals, including director elections and executive compensation, were approved, indicating strong shareholder support and potential for strategic growth.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.